First-line abiraterone or enzalutamide for mCRPC in African American and Non-Hispanic White men

Despite multiple agents receiving approval for treatment of metastatic castration-resistant prostate cancer (mCRPC), African American (AA) men are underrepresented in seminal phase 3 trials in mCRPC. A propensity score-adjusted retrospective cohort study using the Flatiron Health database of 3803 patients with mCRPC, found that among men receiving first-line abiraterone, AA men had significantly longer median overall survival compared with non-Hispanic white (NHW) men (23 vs 17 months). This difference between AA and NHW patients was not seen with first-line enzalutamide. Among NHW men, first-line abiraterone was associated with significantly lower median overall survival than enzalutamide (17 vs 20 months).